The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

BMRN

BioMarin Pharmaceutical Inc.

Healthcare · Biotechnology

Overall research band Strong
Quality Mixed
Valuation Strong
Balance sheet Strong
Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

BioMarin Pharmaceutical Inc. is a biotechnology company specializing in the development and commercialization of treatments for severe and rare disorders, including lysosomal storage diseases and inherited metabolic conditions. Its main products include Vimizim for mucopolysaccharidosis (MPS) IV type A, Naglazyme for MPS VI, Kuvan and Palynziq for phenylketonuria (PKU), Brineura for ceroid lipofuscinosis type 2, Voxzogo for achondroplasia, and Aldurazyme for MPS I. BioMarin also has a robust pipeline, with candidates such as valoctocogene roxaparvovec for severe hemophilia A, BMN 307 for PKU, and BMN 255 for primary hyperoxaluria in clinical trials. The company serves specialty pharmacies, hospitals, government health bodies, distributors, and pharmaceutical wholesalers across the United States, Europe, Latin America, and other global markets, generating revenue through the sale of its pharmaceutical products. BioMarin maintains strategic partnerships with organizations including Sarepta Therapeutics, Ares Trading S.A.

The current research profile is Balanced Opportunity. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC7.2%Model input; read with the evidence status and period context.
Operating margin16.6%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years14.9%Model input; read with the evidence status and period context.
FCF margin22.5%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.